SignatureFD’s Enliven Therapeutics ELVN Stock Holding History
Bought
Maintained
Sold
Other funds holding ELVN
SignatureFD's ELVN Position: Q3 2026 in Review
SignatureFD increased its Enliven Therapeutics (ELVN) stake by 15% in Q3 2026, buying an estimated $2.78K and bringing the position to 387 shares worth $17.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2476.
SignatureFD first reported a position in ELVN in Q2 2025 and has held it in 6 quarters since. 216 funds tracked by Wall St. Rank hold ELVN as of Q3 2026.
- SignatureFD held 387 shares of Enliven Therapeutics worth $17.7K as of Q3 2026.
- SignatureFD bought 51 Enliven Therapeutics shares in Q3 2026, an estimated $2.78K.
- Enliven Therapeutics made up ﹤0.01% of SignatureFD's portfolio in Q3 2026, its #2476 holding.
- SignatureFD first reported a position in Enliven Therapeutics in Q2 2025 and has held it in 6 quarters since.
- 216 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q3 2026.
Based on SignatureFD's 13F filing for Q3 2026, filed 23 Oct 2026.